Version May 2024
Dental aid: Pass the impregnated cord around the neck of the tooth and place into gingival sulcus; leave cord in sulcus for up to 5 minutes; normal tissue moisture, water, or gingival retraction solutions activate impregnated cord. Limit use to one quadrant of the mouth at a time.
There are no dosage adjustments provided in the manufacturer’s labeling.
There are no dosage adjustments provided in the manufacturer’s labeling.
Refer to adult dosing; use with caution.
No data reported.
Hypersensitivity to epinephrine, sulfites, aluminum-containing products, or any component of the formulation; cardiovascular disease, hypertension, hyperthyroidism, diabetes, or congestive glaucoma; concurrent antidepressant use; do not apply to areas of heavy or deep bleeding or overexposed bone
Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.
Other warnings/precautions:
• Appropriate use: Caution should be exercised whenever using gingival retraction cords with epinephrine since it delivers vasoconstrictor doses of racemic epinephrine to patients; the general medical history should be thoroughly evaluated before using in any patient.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Retraction cord, for gingival sulcus placement:
GingiBRAID +:
0e fine: Epinephrine 0.10 – 0.30 mg and aluminum potassium sulfate 0.05 – 0.25 mg per inch
1e small: Epinephrine 0.20 – 0.60 mg and aluminum potassium sulfate 0.15 – 0.35 mg per inch
2e medium: Epinephrine 0.40 – 0.80 mg and aluminum potassium sulfate 0.20 – 0.50 mg per inch
3e large: Epinephrine 0.60 – 1.20 mg and aluminum potassium sulfate 0.30 – 0.80 mg per inch
No
Dental aid: Aids in temporary gingival retraction and hemostasis procedures
None known.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.
Beta-Blockers (Beta1 Selective): May diminish the therapeutic effect of Epinephrine (Racemic). Risk C: Monitor therapy
Beta-Blockers (Nonselective): May enhance the hypertensive effect of Epinephrine (Racemic). Risk C: Monitor therapy
Beta-Blockers (with Alpha-Blocking Properties): May diminish the therapeutic effect of Epinephrine (Racemic). Risk C: Monitor therapy
Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Epinephrine (Racemic). Risk C: Monitor therapy
Epinephrine stimulates alpha1 adrenergic receptors to cause vasoconstriction in blood vessels in gingiva; aluminum potassium sulfate, precipitates tissue and blood proteins
No data reported.
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
